Health & bio
Viridian Elegrobart Phase 3 REVEAL-2 Achieves 50% PRR in Chronic Thyroid Eye Disease
May 5 Phase 3 REVEAL-2 data showed 50% partial response rate (versus 15% placebo) for four-weekly elegrobart dosing, with eight-weekly achieving 54%, securing Q1 2027 BLA filing pathway.
Primary sources · 2